In addition, the results of the differential expression and co-expression analyses indicated that IFI27, MSRB2, and SCO2 may have counteractive regulatory effects when compared to FAM210B and LYRM7 in the progression of SLE, which was corroborated by the outcomes of immune infiltration and GSEA. This evidence concerns the gene MIMS2 and systemic lupus erythematosus.